Reactive perforating collagenosis: a rare side effect associated with sorafenib

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a common primary liver cancer.
• Sorafenib is a multi-kinase inhibitor used to treat advanced HCC.
• Acquired perforating dermatoses are rare skin reactions.

Observation:

• A patient with stage IV HCC developed reactive perforating collagenosis during Sorafenib therapy.
• The skin condition presented as an unusual and rare side effect.
• This adverse event has been documented in only eleven other cases linked to Sorafenib or similar drugs.

Findings:

• The patient's reactive perforating collagenosis was effectively treated with local corticotherapy and systemic antihistamines.
• The successful management highlights potential therapeutic strategies for this rare side effect.
• Histopathological examination is crucial for accurate diagnosis and appropriate treatment.

Implications:

• This case underscores the importance of clinical vigilance for rare drug-induced dermatoses.
• Early recognition and prompt treatment can improve patient outcomes.
• Further research into the mechanisms and management of Sorafenib-associated skin reactions is warranted.